interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Meloxicam

Generic competition · all medicines · read 12 November 2026

Is there a generic of Meloxicam, and who makes it?

Meloxicam appears in 5 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 13 generic makers listed as marketed across them. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 4.6 and 6.3 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Meloxicam5 dosage-form groups in the Orange Book
13generic makers listed
  1. Meloxicam appears in 5 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 13 generic makers listed as marketed across them.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 4.6 and 6.3 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Four or more generic makers listed

Every brand product here is listed as discontinued. 12 generic makers with 24 generic products listed as marketed; the first generic approval is dated 19 July 2006.

2000200520102015202020252030012brand 2000Aiping Pharmaceutical Inc, first approval 19 July 2006Cipla Ltd, first approval 19 July 2006Glenmark Pharmaceuticals Ltd, first approval 19 July 2006Puracap Pharmaceutical Llc, first approval 19 July 2006Zydus Pharmaceuticals Usa Inc, first approval 19 July 2006Macleods Pharmaceuticals Ltd, first approval 20 July 2006Rising Pharma Holdings Inc, first approval 25 July 2006Aurobindo Pharma Ltd, first approval 2 October 2006Yung Shin Pharmaceutical Industrial Co Ltd, first approval 7 December 2006Unichem Laboratories Ltd, first approval 20 December 2006Novitium Pharma Llc, first approval 13 May 2009Ascent Pharmaceuticals Inc, first approval 7 June 2023data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Aiping Pharmaceutical Inc19 July 20062
Cipla Ltd19 July 20062
Glenmark Pharmaceuticals Ltd19 July 20062
Puracap Pharmaceutical Llc19 July 20062
Zydus Pharmaceuticals Usa Inc19 July 20062
Macleods Pharmaceuticals Ltd20 July 20062
Rising Pharma Holdings Inc25 July 20062
Aurobindo Pharma Ltd2 October 20062
Yung Shin Pharmaceutical Industrial Co Ltd7 December 20062
Unichem Laboratories Ltd20 December 20062
Novitium Pharma Llc13 May 20092
Ascent Pharmaceuticals Inc7 June 20232

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Capsule, Oral

One to three generic makers listed

Every brand product here is listed as discontinued. 2 generic makers with 4 generic products listed as marketed; the first generic approval is dated 1 June 2020.

201520202025203002brand 2015Lupin Ltd, first approval 1 June 2020Novitium Pharma Llc, first approval 9 March 2021data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Lupin Ltd1 June 20202
Novitium Pharma Llc9 March 20212

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Qamzova. No generic is listed as marketed.

2020202520302035204001brand 2020data datePatent 12059423 listed to expire 19 July 2040
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 19 July 2040Patent 12059423 drug substance

Tablet, Orally Disintegrating, Oral

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

201520202025203001brand 2018data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Suspension, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Meloxicam. No generic is listed as marketed.

200020052010201520202025203001brand 2004data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.